It has been found that in DLBCL, PDK4 mediates resistance to rituximab by inhibiting CD20 expression [8], yet the specific mechanism by which PDK4 regulates CD20 in DLBCL requires further investigation. The gene discussed is PDK4; the disease is diffuse large B-cell lymphoma.